Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06357403
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-02-19
Brief Title:
Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients
Sponsor:
Medical University of Vienna
Organization:
Medical University of Vienna
Study Overview
Official Title:
Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients a Prospective Multicentre Cohort Study
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AntiXa-ICU
Brief Summary:
The goal of this observational study is to analyse the association between anti-factor Xa activity antiXa and the occurence of venous thromboembolism VTE either deep vein thrombosis andor pulmonary embolism in critically ill patients who are admitted to an intensive care unit The main questions it aims to answer are
What is the association between antiXa and VTE
What is the association between antiXa and symptomatic respectively incidental VTE
How is pharmacological anticoagulation with enoxaparin related to measured antiXa
What is the association between antiXa and bleeding complications
What is the incidence of venous thromboembolism in patients treated at an intensive care unit
How is the occurence of VTE related to patient-centred outcomes such as mortality quality of life length of stay and days outside of the intensive care unithospital
What is the association between antiXa and VTE
What is the association between antiXa and symptomatic respectively incidental VTE
How is pharmacological anticoagulation with enoxaparin related to measured antiXa
What is the association between antiXa and bleeding complications
What is the incidence of venous thromboembolism in patients treated at an intensive care unit
How is the occurence of VTE related to patient-centred outcomes such as mortality quality of life length of stay and days outside of the intensive care unithospital
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None